Compounding Chemotherapy Market Research Report - Forecast till 2027

Compounding Chemotherapy Market: Information By Dose (Chemotherapeutic and Non-Chemotherapeutics), By Compounding Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration), By Delivery Method (Gravimetric Automated Compounding Device (Weight-Based) and Volumetric Automated Compounding Device (Volume-Based)), By Sterility (Sterile and Non-Sterile), By Technology (With Robotic Arms and Without Robotic Arms), By Compounder Type (Pharmoduct, Equashield Pro, Medimix, Integra, Others), By Application (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/8901-CR | December 2020 | Region: Global | 193 pages

Compounding Chemotherapy Market Analysis

The compounding chemotherapy market is showing significant growth. Compounding of drugs makes them patient-specific which is the biggest advantage. Compounding chemotherapy can minimize the risk of underdose or overdose of drugs for a patient. Therefore, owing to its numerous advantages. 

There is a substantial rise in the incidence of diseases such as cancer, bone marrow diseases, immunity disorders, etc. which require chemotherapy treatment. An increase in pollution levels and rising incidence of such diseases are generating demand for compounding chemotherapy. The market is estimated to grow at a CAGR ( Compound Annual Growth Rate ) of 6.04 % over the current forecast period ( 2020-2027 ). 

Compounding requires expertise, only the best professionals can perform it. However, with the advent of technology, automated compounding devices are bringing a change in the market. Moreover, the market will see a new dawn, if regulatory authorities start verifying the effectiveness of compounded drugs. The valuation of the compounding chemotherapy market is expected to reach USD 635.58 Million by the end of the forecast period in 2027.  

Covid-19 analysis

Covid 19 had a huge impact on the drug production and delivery market. The reluctance of patients to approach hospitals and clinics,  owing to virus fear, caused a decline in demand. Hence, the overall production was down.  

Compounding chemotherapy requires many drug formations but due to supply chain disruptions, there was a halt in production. The restrictions on the movement of goods and people had a severe impact on the market. However,  government support received by the pharmaceutical industry during the period is boosting the growth. The market is expected to catch the earlier growth rate very soon.  

Market dynamics


Compounding the drugs offers several advantages to the traditional method of prescription. Compounding chemotherapy checks the overdose or underdose of particular compounds in the market available chemotherapeutic drugs. Therefore, the ability to develop patient-specific drugs is gathering market demand for compounding chemotherapy. 

The technological advancements in the compounding of medicinal drugs to predict accurate dosage are the major driving factor. Moreover, compounding helps to make drugs allergen-free. It also allows alternative dosages to access the expired medicine. Thus, these factors are increasing the demand for compounded drugs in the market. Furthermore, the rise in the incidence of cancer and similar other diseases is to fuel the market growth.  


There is no legal system to check the efficacy of compounded drugs. Hence, these may also prove to be harmful and even fatal if it comes out of inexperienced hands. Therefore, the uncertainty about the success rate is a major restraint to the market growth.

Lack of proper infrastructure for compounding in many pharmacies may lead to a substandard product. Moreover, Compounding under insanitary conditions causes widespread public harm. The 2012  fungal meningitis outbreak in the USA which caused 60 deaths is a reminder of the need for a proper methodology. Therefore,  compounded drugs are not FDA or any regulatory authority approved, which is a major hindrance to the compounding chemotherapy market. 

Technology analysis

Compounding chemotherapy is a method of developing chemotherapy drugs according to the patient's requirements and feasibility. This is achieved by modification or mixing of the constituents of the market-available drug brands.

Compounding is of great importance in removing compounds or colors in market brands that may be allergic to some patients. Moreover, if a child or an aged person cannot consume tablets then one can change the form by compounding to liquid syrups or injections by compounding. Therefore, compounding chemotherapy can overcome the limits of traditional chemotherapy to make health drugs more effective.  

Study objectives

This report aims to provide an in-depth analysis of the compounding chemotherapy market. The specific objectives of this market report on compounding chemotherapy are  given below:

  • To analyze and forecast the compounding chemotherapy market in terms of value and volume.

  • To provide information about the impact of covid 19 on the compounding chemotherapy market and market growth thereafter.

  • To identify the problems and prospects of the compounding chemotherapy market.

  • To give details about the technological viability of the product.

  • To provide an overview of the regional markets and potentially growing segments.

  • To highlight the key players of the industry. 

Segment overview

Segmentation of the Compounding Chemotherapy Market, by dose

  • Chemotherapeutic and

  • non-chemotherapeutics 

The chemotherapeutic segment holds the largest market share. The higher efficacy of chemotherapeutic drugs is promoting market growth. Moreover, the aging population and the increasing cancer cases are the growth boosters for this segment.  

Segmentation of the compounding chemotherapy market, by compounding type 

  • Pharmaceutical ingredient alteration (PIA)

  • Currently unavailable pharmaceutical manufacturing (CUPM)

  • Pharmaceutical dosage alteration (PDA).

Pharmaceutical dosage Alteration ( PDA) is the dominating market segment. It held about 40 % of the total market share in 2019. This is the easiest method among others and gives good effects. Moreover, less technical expertise is needed to perform PDA than other forms of modification. 

Segmentation of the Compounding Chemotherapy Market, by the delivery method

  • Gravimetric automated compounding device (weight-based)

  • Volumetric automated compounding device (volume-based) 

The Gravimetric automated compounding device (weight-based) occupies the largest market share. Easy handling of gravimetric products makes it the leading market segment. 

Segmentation of The compounding chemotherapy market, by sterility

  • Sterile

  • Non-sterile

The sterile segment holds more than 50 percent of the market share, so it is a dominating segment.  Injections and infusions that have higher efficiency need to be strictly sterile,  thereby ensuring its demand. 

Segmentation of the compounding chemotherapy market, by technology

  • With robotic arms

  • Without robotic arms

The robotic arm segment holds the major market share. Moreover, it is also having a high CAGR of 6.4 percent over the forecast period. It is due to the higher accuracy and better predictability of automated machines. 

Segmentation of the global compounding chemotherapy market, by compounder type

  • Pharmoduct

  • Equashield Pro

  • Medimix

  • Integra

  • others

The pharmoduct segment occupies the major market share. The dominance is due to its automated sterile technology and higher working efficiency.  

Segmentation of the compounding chemotherapy market, by application

  • Breast cancer

  • Blood cancer

  • Prostate cancer

  • Gastrointestinal cancer

  • Respiratory/lung cancer

  • Others

The breast cancer segment is the largest and the fastest-growing market for compounding chemotherapy. The higher prevalence of breast cancer among other types makes it the leading segment. Prostate cancer and Lung cancer follow the list in terms of market value. 

Regional analysis

  • The Americas

    • North America

      • US

      • Canada

      • Mexico

    • Latin America 

  • Europe

    • Western Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Rest of Europe

    • Eastern Europe 

  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Rest of Asia-Pacific 

  • Rest of the world ( RoW )

    • The Middle East

The American segment is the major regional market for the compounding chemotherapy market. The rise in the number of cancer cases and the increasing geriatric population has been pushing the growth. Moreover, better health care infrastructure and favorable government policies in this region are supporting the market growth.

Europe is the second-largest regional market of compounding chemotherapy by value. Better research facilities for compounding drugs and higher healthcare spending by the government are sustaining the growth. Moreover, the increasing geriatric population and higher disposable income of the people are expected to fuel the growth. 

The Asia Pacific is the fastest-growing segment. The rising economies of this region are better funding the healthcare sector which is driving the market growth. Moreover, rising disposable income is bringing more people under health care coverage. Furthermore, increasing literacy rate and the growth of the R&D sector in this region is to boost the market growth. 

Competitive landscape

The market for compounding chemotherapy is dominated by several global giants. The key global players are:-

  • Braun Melsungen AG

  • Pfizer Inc.

  • Baxter

  • Grifols SA

  • The Metrix Company

  • Added Pharma

  • Equashield

  • Millers Pharmacy

  • Comecer S.P.A.

  • Omnicell

  • Icon group

  • Dedalus Group

  • Arxium

  • Sterline S.R.L.

  • Loccioni 

Recent developments

  • In October 2019, Equashield, a leading provider of closed system transfer devices (CSTD), announced it would provide its service to the Netherlands, for the first time in Europe. 

Intended audience

This report will be beneficial for every stakeholder of the compounding chemotherapy market. It will help in decision making for those directly connected with the industry such as:

  • Manufacturers of chemotherapy drugs

  • Medical Research and Development Institutes

  • Hospitals and Clinics

  • Traders and Distributors

  • Patients 

Report overview

This report provides complete details on the compounding chemotherapy market in terms of current value and future forecasts. We have also identified the problems and prospects of the given market. 

The technological analysis of the product will help in knowing the product better and in decision making. Moreover, this report contains a detailed analysis of every segment of the given market for the current forecast period. This report has also highlighted the key players and the current developments in the compounding chemotherapy market. 

Report Scope:
Report Attribute/Metric Details
  Market Size   635.58 Million
  CAGR   6.04%
  Base Year   2020
  Forecast Period   2027
  Historical Data   2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.
  Key Market Opportunities   Opioid scarcity
  Key Market Drivers

  • Technical Advances
  • Cutting-Edge Strategies\r\n

  • Speak to Analyst Ask for Customization

    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.